NTRK mutated Pancreatic Cancer
NTRK mutated Pancreatic Cancer
Scroll to Continue
FDA Approves Calquence (Acalabrutinib) Plus Chemoimmunotherapy for Previously Untreated Mantle Cell Lymphoma
Patients with mantle cell lymphoma who are ineligible for autologous hematopoietic stem cell transplantation have a new first-line treatment option
Kadcyla (Trastuzumab Emtansine) in HER2-Positive Early Breast Cancer with Residual Invasive Disease
Long-term results demonstrate improved survival and sustained improvement in invasive disease-free survival for study patients treated with Kadcyla vs Herceptin
Lumakras (Sotorasib) in combination with Vectibix (Panitumumab) FDA Approved for Metastatic Colorectal Cancer with KRAS G12C Mutation
CODEBreaK 300 study demonstrated combination more than doubled progression-free survival compared to physician’s choice of standard of care
